Search Within

Myeloma

Formats
  1. Meeting Abstract (557)
  2. Journal Article (368)
  3. Review (37)
  4. Research Letter (21)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (7)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (1016)
  2. Department of Medicine (1016)
  3. Hematologic Malignancies, Division of (1016)
  4. Hematologic Malignancies Research (669)
  5. Survivorship Research (374)
  6. Sloan Kettering Institute Postdocs (306)

More Groups

People
  1. Alexander Lesokhin (381)
  2. Hani Hassoun (339)
  3. Carl Landgren (336)
  4. Sham Mailankody (297)
  5. Malin Hultcrantz (274)
  6. Heather Landau (249)

More People

Years
  1. 2025 (28)
  2. 2024 (82)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (317)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (86)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (24)

More Publications

Publishers
  1. American Society of Hematology (340)
  2. Elsevier Inc. (160)
  3. American Society of Clinical Oncology (88)
  4. Nature Publishing Group (87)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (1016)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Modern multiple myeloma therapy: Deep, sustained treatment response and good clinical outcomes
    Journal Article

    Landgren, O.; Iskander, K.
    Journal of Internal Medicine (2017)

    Fulltext@MSK | Save
  • Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
    Journal Article

    Naidoo, J.; Wang, X.; Woo, K. M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J. E.; Segal, N. H.; Callahan, M. K.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: Efficacy and analysis of risk factors associated with poor stem cell collection efficiency*
    Journal Article

    Ogunniyi, A.; Rodriguez, M.; Devlin, S.; Adel, N.; Landau, H.; Chung, D. J.; Lendvai, N.; Lesokhin, A.; Koehne, G.; Mailankody, S.; more...
    Leukemia and Lymphoma (2017)

    Fulltext@MSK | Save
  • Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis
    Journal Article

    Landau, H.; Smith, M.; Landry, C.; Chou, J. F.; Devlin, S. M.; Hassoun, H.; Bello, C.; Giralt, S.; Comenzo, R. L.
    Leukemia (2017)

    Fulltext@MSK | Save
  • Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone
    Journal Article

    Manasanch, E. E.; Fernández de Larrea, C.; Zingone, A.; Steinberg, S. M.; Kwok, M.; Tageja, N.; Bhutani, M.; Kazandjian, D.; Roschewski, M.; Wu, P.; more...
    Leukemia and Lymphoma (2017)

    Fulltext@MSK | Save
  • History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: A population-based study
    Journal Article

    Lindqvist, E. K.; Landgren, O.; Lund, S. H.; Turesson, I.; Hultcrantz, M.; Goldin, L.; Björkholm, M.; Kristinsson, S. Y.
    Annals of Hematology (2017)

    Fulltext@MSK | Save
  • A phase lb dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts
    Meeting Abstract

    Vij, R.; Lendvai, N.; Martin, T. G.; Baz, R. C.; Campana, F.; Mazuir, F.; Charpentier, E.; Benson, D. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Richter, J. R.; Martin, T. G.; Vij, R.; Cole, C.; Atanackovic, D.; Zonder, J. A.; Kaufman, J. L.; Mikhael, J.; Bensinger, W.; Dimopoulos, M. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients
    Meeting Abstract

    Mailankody, S.; Korde, N.; Roschewski, M. J.; Christofferson, A.; Boateng, M.; Zhang, Y.; Manasanch, E. E.; Kazandjian, D. G.; Kwok, M.; Bhutani, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Food and Drug Administration analysis of 1332 single patient and emergency use expanded access (compassionate use) requests for patients with cancer over a duration of three years (2012-2014)
    Meeting Abstract

    Lemery, S. J.; Mailankody, S.; Kazandjian, D.; Smit, M. A. D.; Blumenthal, G. M.; Kim, T.; Keegan, P.; Pazdur, R.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save